Cotización Vortex Energy - VRTX

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

0.095

Postura de Compra

0.095

Postura de Venta

0.10

Volume Operado de la Acción

38,850

0.095 Rango del Día 0.10

0.095 Rango de 52 semanas 0.85

Precio Anterior

0.095

Precio de Apertura

0.095

Hora

3000

0.095

Última hora de negociación

Volumen promedio (3 m)

80,251

Volumen financiero

Precio Promedio Ponderado

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations at Merrill Lynch's Global Pharmaceutical, Biotech...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Merck & Co., Inc...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- Encouraging Results Support...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.02	-17.3913043478	0.115	0.115	0.095	110934	0.10165982	CS
4	-0.045	-32.1428571429	0.14	0.14	0.095	128680	0.11069228	CS
12	-0.105	-52.5	0.2	0.21	0.095	80251	0.13672547	CS
26	-0.16	-62.7450980392	0.255	0.27	0.095	70503	0.1761953	CS
52	-0.635	-86.9863013699	0.73	0.85	0.095	162709	0.42094895	CS
156	-0.005	-5	0.1	2.32	0.095	205654	0.9674229	CS
260	-0.005	-5	0.1	2.32	0.095	205654	0.9674229	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
WRUNWaverunner Capital Inc	$ 0.015 (200.00%)	81.11k
ULTAUltra Brands Ltd	$ 0.03 (200.00%)	91k
VTALJustera Health Ltd	$ 0.01 (100.00%)	385k
MJRXGlobal Health Clinics Ltd	$ 0.02 (100.00%)	3.26k
VIKAvila Energy Corporation	$ 0.01 (100.00%)	51.65k
FREEFree Battery Metal Limited	$ 0.005 (-50.00%)	28.5k
WINWindfall Geotek Inc	$ 0.01 (-50.00%)	717.2k
APPGlobal Compliance Applications Corp	$ 0.005 (-50.00%)	300.1k
GCPGolcap Resources Corp	$ 0.12 (-38.46%)	5.5k
GFCOGood Flour Corp	$ 0.125 (-37.50%)	5k
GRHKGreenhawk Resources Inc	$ 0.15 (36.36%)	5.15M
CRUZCruz Battery Metals Corp	$ 0.055 (22.22%)	4.13M
LEEFLeef Brands Inc	$ 0.025 (25.00%)	3.65M
MISMistango River Resources Inc	$ 0.03 (-14.29%)	1.26M
AUCUInflection Resources Ltd	$ 0.21 (10.53%)	1.25M